A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Recruiting
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with lo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: UC Irvine Medical Center, Costa Mesa, California +29 locations
Conditions: Advanced Liver Cancers
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Recruiting
This phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a fewer number of days than tradition radiation therapy courses for Merkel cell carcinoma. This may be less suppressive of the immune response to tumors and should be helpful for patient convenience.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Merkel Cell Carcinoma
OssDsign® Spine Registry Study ("Propel")
Recruiting
The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/03/2025
Locations: Community Health Partners Neuroscience, Fresno, California +12 locations
Conditions: Degenerative Disc Disease, Spinal Stenosis
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Recruiting
Identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. We using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer, Breast Cancer, Colorectal Cancer
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Recruiting
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
06/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Multiple Myeloma
A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
Recruiting
The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 \[NCT05350072\] or CVAY736A2302 \[NCT05349214\]). * The study treatment is ianalumab 300 mg in a 2 mL pre-filled syringe (PFS) or in a 2 mL autoinjector (AI) for injection. All participants will receive ianalumab either monthly or every 3 months. * The treatment duratio... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Providence Medical Foundation, Fullerton, California +196 locations
Conditions: Sjogrens Syndrome
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Recruiting
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Gender:
ALL
Ages:
Between 6 years and 75 years
Trial Updated:
06/03/2025
Locations: University of California Irvine - Accepting Adult Patients, Orange, California +16 locations
Conditions: Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
Recruiting
Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: UC Davis, Sacramento, California +9 locations
Conditions: PSC
Time Restricted Eating in Alzheimer's Disease
Recruiting
This pilot and feasibility study will enable the research team to determine the feasibility of implementing a time-restricted eating regimen among adults with mild cognitive impairment (MCI) and the impact of time-restricted eating on cognitive performance and biomarkers of metabolic health in this population. Study staff will execute the specific aims using a pre-post, non-randomized study design in which all participants receive the intervention. The intervention is a 16/8 time-restricted eati... Read More
Gender:
ALL
Ages:
Between 55 years and 89 years
Trial Updated:
06/03/2025
Locations: Arizona State University, College of Health Solutions, Phoenix, Arizona +1 locations
Conditions: Mild Cognitive Impairment (MCI)
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Recruiting
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado +7 locations
Conditions: Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
Recruiting
This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients with mild cognitive difficulties during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruit... Read More
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
06/03/2025
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina
Conditions: Breast Cancer, Locally Advanced Breast Cancer, Cognitive Impairment, Cognitive Decline, Cognitive Change, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
A Study of Varenicline in the Treatment of Visceral Sensation
Recruiting
The purpose of this study is to evaluate the effect of varenicline on rectal sensation, based on ascending method of limits and on graded rapid phasic distensions in participants with non-constipation IBS and chronic abdominal pain.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/03/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Irritable Bowel Syndrome